MINI LONG - NOVO-NORDISK B | Market Closed - Börse Stuttgart 14:59:28 2024-06-25 EDT | ||
| 18.6 EUR | +5.80% |
|
| Current month | +16.54% | ||
| 1 month | +13.83% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-25 | 18.6 | +5.80% |
| 24-06-24 | 17.58 | -1.12% |
| 24-06-21 | 17.78 | +1.25% |
| 24-06-20 | 17.56 | +0.40% |
| 24-06-19 | 17.49 | +0.69% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 02:59 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MA8FBT |
| ISIN | DE000MA8FBT3 |
| Date issued | 2021-08-09 |
| Strike | 329.6 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.56 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 18.81 € |
|---|---|
| Lowest since issue | 0.13 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,028
DKK
Average target price
938.1
DKK
Spread / Average Target
-8.74%
- Stock Market
- Certificates
- Certificat
